Home > Press > Trellis Bioscience Raises $10 Million in Series B Venture Round
Trellis Bioscience, Inc., a privately held biotechnology company, announced today that it has raised $10 million in a Series B Preferred Stock venture capital financing. New investor Novartis Bioventures Ltd. led the round, with the participation of additional new investors Pac-Link Bio Venture Investment Corporation and Sagamore Bioventures LLC. Previous investors, Easton-Hunt Capital Partners, LP and Morgenthaler Partners VII LP also participated in the financing. Proceeds from the financing will be used to develop Trellis' own product candidates, as well as its corporate partnering product candidates, and for general corporate purposes.
Trellis Bioscience Raises $10 Million in Series B Venture Round
SOUTH SAN FRANCISCO, CA | Posted on February 13th, 2007
Trellis additionally announced that Markus Goebel, M.D., Ph.D., managing director of Novartis Bioventures, will join the Trellis Board of Directors.
"We are very pleased to have the participation of this high quality group of venture investors whose support further validates Trellis' technology and business strategy," said Brian C. Cunningham, Trellis' Chief Executive Officer. "This financing will help to transform Trellis from a technology platform company to a product-oriented biotechnology firm that generates its own therapeutic candidates in the areas of infectious disease and oncology. At the same time, we will continue to partner with other companies to commercially validate the advantages of Trellis CellSpot(TM) technology to rapidly identify important therapeutic antibodies as well as high-producing cell lines that can dramatically improve the productivity of antibody and other protein manufacturing processes."
About Trellis Bioscience
Trellis Bioscience, Inc. has developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics. The company's proprietary CellSpot(TM) platform is at the convergence of nanotechnology, software, digital microscopy and biology and allows for a parallel evaluation of millions of cells simultaneously in a way that enables the valuable one in one million cells to be reliably identified and recovered. The technology has broad application in the discovery and production process development of therapeutic proteins. In addition to applying CellSpot(TM) to the discovery and manufacturing needs of partners, Trellis is developing a pipeline of native human antibodies for the treatment of infectious disease and oncology. More information about Trellis Bioscience can be found at http://www.trellisbio.com .
For more information, please click here
Trellis Bioscience, Inc.
Brian C. Cunningham, 650-616-1121
Joan Kureczka, 415-821-2413
Copyright © Business Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015
Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015
Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference February 17th, 2015
Iran 1st among Islamic Nations in Scientific Production, Nanotechnology February 16th, 2015
UT Dallas engineers twist nanofibers to create structures tougher than bulletproof vests March 27th, 2015
Novel nanoparticle therapy promotes wound healing March 27th, 2015
Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015
Using magnetic fields to understand high-temperature superconductivity: Los Alamos explores experimental path to potential 'next theory of superconductivity' March 27th, 2015